OKYO Pharma Limited

EMMLD

GG00BMFG5F62

OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Companyâs principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Companyâs technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Companyâs wholly owned subsidiary is OKYO Pharma US Inc.

Sector

Pharmaceuticals

Calendar

2024-05-03 - Association for Research in Vision and Ophthalmology Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.5 USD

Average target price

7 USD

Spread / Average Target

+366.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
OKYO PHARMA LIMITED	-13.56%	49.85M
CSL LIMITED	-3.93%	86.16B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.17B
BIOGEN INC.	-17.53%	31.47B
UCB	+54.44%	25.24B
BIOMARIN PHARMACEUTICAL INC.	-13.05%	15.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
INCYTE CORPORATION	-15.51%	11.89B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.84B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 03:59:35 2024-05-02 pm EDT			5-day change	1st Jan Change
1.545 ^USD	+3.00%		+5.76%	-13.56%

Mar. 22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
Mar. 22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	Mar. 22	MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	Mar. 22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	Mar. 20	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	Feb. 09	MT
Sector Update: Health Care	Feb. 09	MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	Feb. 09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	Feb. 09	CI
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	Jan. 31	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	Jan. 08	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	Dec. 04	CI
HC Wainwright Initiates Coverage on OKYO Pharma with Buy Rating, $4 Price Target	Nov. 02	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	23-10-09	MT
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	23-10-09	MT
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	23-10-09	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	23-10-05	CI
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	23-09-15	MT
Top Premarket Decliners	23-09-15	MT
Sector Update: Health Care Stocks Rising Late Afternoon	23-09-14	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-09-14	MT
OKYO Pharma Prices $4 Million Share Offering	23-09-14	MT
Top Premarket Decliners	23-09-14	MT
OKYO Pharma Plans Share Offering; Stock Down After-Hours	23-09-13	MT
Top Premarket Decliners	23-09-13	MT
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	23-09-08	CI
Top Premarket Decliners	23-08-31	MT

OKYO Pharma Limited

Equities